Rezolute to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:

Event: Cantor Global Healthcare Conference
Date: September 9-11, 2026

Event: H.C. Wainwright 28^th Annual Global Investment Conference
Date: September 14-16, 2026

Event: Morgan Stanley 24^th Annual Global Healthcare Conference
Date: September 14-16, 2026

Management will be participating in fireside chats and one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Cantor, H.C. Wainwright, and Morgan Stanley representatives.

About Rezolute, Inc.

Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com.

Rezolute Contacts:

Christen Baglaneas
[email protected]
508-272-6717

Carrie McKim
[email protected]
336-608-9706

You May Also Be Interested In

• Crypto News: Pepeto Announces $10.917M Raised Following the Shiba Inu Success While Cardano Price Prediction Turns Bullish
• MFour Expands Digital Ad Exposure Intelligence to ChatGPT and Audio Streaming Platforms
• Rosina Foods Launches Five New Frozen Meatball Innovations Nationwide